𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study

✍ Scribed by Sarah A. Taylor; Thomas Fleming; Daniel D. Hoff; Joseph D. McCracken; Ronald M. Bukowski; Robert W. Talley; Robert B. Natale; J. T. Guy; Wolfram E. Samlowski; John H. Costanzi

Publisher
Springer US
Year
1990
Tongue
English
Weight
242 KB
Volume
8
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

✦ Synopsis

Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v. repeated every three weeks. Myelosuppression in the form of leukopenia was the major toxicity. There were no responses in twenty-four evaluable patients.

πŸ“œ SIMILAR VOLUMES

Phase II evaluation of esorubicin (4β€² de
Phase II evaluation of esorubicin (4β€² deoxydoxorubicin) in pancreatic adenocarcinoma: A Southwest Oncology Group study
✍ Clarence B. Vaughn; Sydney E. Salmon; Thomas R. Fleming πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 335 KB

Esorubicin (4' deoxydoxorubicin) is a new analogue of the anthracycline, doxorubicin. This compound lacks the hydroxyl group at 4' position on the amino sugar of the anthracycline. Phase II study was designed to determine the clinical response rate and to define the qualitative and quantitative toxi

Phase II evaluation of bleomycin. A Sout
Phase II evaluation of bleomycin. A Southwest Oncology Group study
✍ Charles D. Haas; Charles A. Coltman Jr.; Jeffrey A. Gottlieb; Arthur Haut; James πŸ“‚ Article πŸ“… 1976 πŸ› John Wiley and Sons 🌐 English βš– 369 KB πŸ‘ 2 views

Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/mz was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and

Phase II trial of carboplatin and paclit
Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma : A Southwest Oncology Group study
✍ Ulka N. Vaishampayan; James R. Faulkner; Eric J. Small; Bruce G. Redman; Wayne L πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 86 KB

## Abstract ## BACKGROUND The purpose of the study was to assess the efficacy and toxicity of carboplatin and paclitaxel administered every 3 weeks in patients with advanced urothelial carcinoma, previously treated with cisplatin‐based therapy. ## METHODS Eligibility included metastatic or local